ADXN.SW Addex Therapeutics (SIX) +11.43% to CHF0.039 23 Mar 2026: catalysts ahead

ADXN.SW stock led today’s small-cap gains on the SIX, rising 11.43% to CHF 0.039 on 23 Mar 2026 as volume jumped to 339,147 shares. The move followed renewed investor interest in Addex Therapeutics Ltd’s CNS pipeline and higher-than-average trading versus a 50-day average of 212,148. We review why this intraday gain matters, how liquidity and fundamentals look in Switzerland, and what the Meyka AI grade and forecasts imply for short- and medium-term traders.

Price action and trading data for ADXN.SW stock

ADXN.SW stock closed at CHF 0.039, up 0.004 or 11.43% from a previous close of CHF 0.035. Intraday range hit CHF 0.035 to CHF 0.0424 with volume 339,147, above the average volume of 212,148. The stock’s relative volume of 1.58 shows higher attention today on the SIX in Switzerland. Year high and low sit at CHF 0.085 and CHF 0.0336 respectively, and short-term moving averages remain above the current price (50-day CHF 0.04916, 200-day CHF 0.05661).

Fundamental snapshot: valuation and financial metrics for ADXN.SW stock

Addex Therapeutics (ADXN.SW) is a Geneva-based biotech focused on CNS small molecules. Market cap is CHF 5,884,004.00 with 150,871,899 shares outstanding. Latest reported EPS is -0.06 and the trailing PE is -0.65, reflecting development-stage losses. Key ratios: price-to-book 0.74, price-to-sales 42.43, and current ratio 2.01, which indicates short-term liquidity. Enterprise value is CHF 3,733,351.00, and free cash flow per share is -0.01399.

Technical view and momentum signals for ADXN.SW stock

Momentum indicators show scarcity of bullish conviction: RSI at 37.31 sits below neutral, CCI at -109.17 flags oversold conditions, and ADX at 20.78 signals a weak trend. Bollinger bands centre around CHF 0.04. Price sits under both the 50- and 200-day averages, implying the short-term trend is lower despite today’s gain. Watch volume spikes and whether price closes above CHF 0.042 for confirmation of follow-through.

Meyka AI grade and model forecast for ADXN.SW stock

Meyka AI rates ADXN.SW with a score out of 100: 67 (B) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a quarterly price of CHF 0.05, implying an implied upside of 28.21% vs the current CHF 0.039. The model also shows a monthly target CHF 0.03 and a one-year projection CHF 0.03164. Forecasts are model-based projections and not guarantees.

Catalysts, risks and sector context for ADXN.SW stock

Catalysts include clinical updates for Dipraglurant and potential licensing activity; Addex lists partnerships with Janssen and Indivior which can re-rate the stock. Key risks are continued cash burn, negative EPS, and low liquidity typical for micro-cap biotechs in the Swiss Healthcare sector. The broader Healthcare sector on SIX shows stronger profitability metrics (avg PE ~26.77), underlining Addex’s developmental-stage valuation gap.

Valuation, analyst cues and trading strategy for ADXN.SW stock

Valuation is speculative: price-to-book under 1.00 suggests book backing, while price-to-sales near 42.43 reflects minimal revenues. On signs of positive clinical data, short-term traders may target CHF 0.05 resistance; longer-term investors should demand clearer cash runway and progress. Use stop-losses given volatility and thin order book. For deeper company detail consult Addex’s site and our Meyka page: Addex Therapeutics website and Meyka AI ADXN.SW page.

Final Thoughts

ADXN.SW stock’s 11.43% gain to CHF 0.039 on 23 Mar 2026 was volume-backed and fits a pattern of short, sharp moves in development-stage biotech names on the SIX. Fundamentals show a small market cap (CHF 5,884,004.00), negative EPS (-0.06) and tight cash per share (0.01947), so gains should be assessed against funding risk. Meyka AI rates ADXN.SW 67 out of 100 (B, HOLD) and its forecast model projects a quarterly target of CHF 0.05, implying ~28.21% upside from today’s close; the one-year model point is CHF 0.03164, implying downside versus current price. Traders attracted to the recent move should confirm follow-through above CHF 0.042 and monitor clinical or licensing catalysts. Long-term holders should prioritise cash runway, upcoming earnings announcement on 27 Apr 2026, and sector comparables in Healthcare, using tight position sizing due to volatility and low liquidity. Meyka AI provides this as an AI-powered market analysis platform; forecasts are projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.